Pralatrexate in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL): Relationship between response and survival

被引：1
|
作者：
Shustov, A. R.
Pro, B.
Horwitz, S. M.
Jacobsen, E. D.
Boyd, A.
Fruchtman, S. M.
O'Connor, O.
机构：
[1] Seattle Canc Care Alliance, Seattle, WA USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Alios Therapeut, Westminster, CO USA
[6] Alios Therapeut, Princeton, NJ USA
[7] NYU, Inst Canc, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.8054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8054
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [1] PRALATREXATE ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL): RELATIONSHIP BETWEEN RESPONSE AT CYCLE 1 AND SUBSEQUENT SURVIVAL
    Coiffier, B.
    Zinzani, P. L.
    Gisselbrecht, C.
    Shustov, A.
    Pro, B.
    Horwitz, S.
    Jacobsen, E.
    Koutsoukos, T.
    Fruchtman, S.
    O'Connor, O.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 122 - 122
  • [2] Safety and Management of Pralatrexate Treatment in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL).
    Pinter-Brown, Lauren
    Horwitz, Steven M.
    Pro, Barbara
    Zinzani, Pier Luigi
    Gisselbrecht, Christian
    Cortelli, Barbara MacGregor
    Fruchtman, Steven
    O'Connor, Owen A.
    BLOOD, 2009, 114 (22) : 668 - 668
  • [3] PRALATREXATE REVERSES THE TREND TO PROGRESSIVE RESISTANCE IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)
    Coiffier, B.
    Zinzani, P.
    Koutsoukos, A.
    O'Connor, O.
    ANNALS OF ONCOLOGY, 2011, 22 : 202 - 202
  • [4] Pralatrexate: Phase 1/2 Study in Japanese Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)
    Maeda, Yoshinobu
    Tobinai, Kensei
    Nagai, Hirokazu
    Nakane, Takahiko
    Shimoyama, Tatsu
    Nakazato, Tomonori
    Sakai, Rika
    Ishikawa, Takayuki
    Izutsu, Koji
    Ueda, Ryuzo
    BLOOD, 2016, 128 (22)
  • [5] Pralatrexate Induces Responses in Patients with Highly Refractory Peripheral T-Cell Lymphoma (PTCL).
    Pettengell, Ruth
    Coiffier, Bertrand
    Narayanan, Geetha
    Hurtado de Mendoza, Fernando
    Digumarti, Raghunadharao
    Gomez, Henry
    Zinzani, Pier Luigi
    Schiller, Gary J.
    Rizzieri, David A.
    Cernohous, Paul
    Wang, Lixia
    Singer, Jack W.
    BLOOD, 2009, 114 (22) : 669 - 669
  • [6] Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Jennifer, Zhao C.
    Sara Mohamed, Jaszczur
    Salma, Afifi
    Francine, Foss
    EXPERT REVIEW OF HEMATOLOGY, 2020, 13 (06) : 577 - 583
  • [7] PRALATREXATE IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA; REPORT ON THREE PATIENTS
    Tezel, Pinar
    Bulbul, Hale
    Koseoglu, Fatos Dilan
    Davulcu, Eren Arslan
    Ulusoy, Yusuf
    Soyer, Nur Akad
    Sahin, Fahri
    Tombuloglu, Murat
    Saydam, Guray
    LEUKEMIA RESEARCH, 2017, 61 : S51 - S51
  • [8] Safety and efficacy of pralatrexate in the treatment of patients with relapsed or refractory peripheral T-cell lymphoma
    Marchi, Enrica
    O'Connor, Owen A.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2012, 3 (04) : 227 - 235
  • [9] PROPEL: Results of the pivotal, multicenter, phase II study of pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
    O'Connor, O.
    Pro, B.
    Pinter-Brown, L.
    Popplewell, L.
    Bartlett, N.
    Lechowicz, M.
    Savage, K.
    Coiffier, B.
    Saunders, M.
    Horwitz, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
    Rodd, Annabelle L.
    Ververis, Katherine
    Karagiannis, Tom C.
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6 : 305 - 314
12345